From the Food and Drug Administration.
Crawford
Lester M
LM
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D007205:Indium Radioisotopes; D008148:Lovastatin / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D015021:Yttrium Radioisotopes
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan; D008148:Lovastatin